Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bio-Thera Kicks Off Ustekinumab Trial

Phase I Study Follows Similar Efforts From Rival Stelara Biosimilars

Executive Summary

China’s Bio-Thera solutions has announced the start of Phase I trials for its ustekinumab biosimilar. The project is one among several potential rivals to Stelara in the works from a host of developers.

You may also be interested in...



Bio-Thera Conducts Simponi Phase III Trial

China’s Bio-Thera Solutions has announced the start of Phase III trials for its BAT2506 proposed biosimilar golimumab rival to Janssen’s Simponi.

BioFactura Joins Stelara Biosimilar Crowd

Janssen’s Stelara is continuing to attract a growing crowd of proposed biosimilar rivals, with BioFactura becoming the latest to throw its hat into the ring after kicking off Phase I trials for its BFI-751 version.

Meiji Seika Is Latest To Kick Off Ustekinumab Phase III

Meiji Seika and Dong-A Socio Holdings have become the latest developers to announce the start of Phase III trials for an ustekinumab biosimilar rival to Stelara.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150226

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel